Drug Combination Details

General Information of the Combination (ID: C62662)
Name Arsenic trioxide   NP Info  + Vorinostat   Drug Info 
Structure +
Disease
Lung cancer [ICD-11: 2C25]
Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [1]
                    Molecule(s)
                    Regulation		 Up-regulation Expression CDKN1A  Molecule Info 
Pathway MAP
Up-regulation Cleavage PARP1  Molecule Info 
Pathway MAP
                    In-vitro Model A-549 CVCL_0023 Lung adenocarcinoma Homo sapiens
NCI-H1299 CVCL_0060 Lung large cell carcinoma Homo sapiens
                    In-vivo Model Male Balb/c nude mice at 4-6 weeks of age were injected sc in the hind limb with 1 * 107 H1299 cells in 100 ul of phosphate-buffered saline.
                    Experimental
                    Result(s)		 Combined treatment with ATO and SAHA resulted in enhanced suppression of non-small-cell lung carcinoma in vitro in H1299 cells and in vivo in a xenograft mouse model.
References
Reference 1 Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide. Toxicol Appl Pharmacol. 2011 Nov 15;257(1):59-66.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link